

Kirsty Stewart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6283245/publications.pdf>

Version: 2024-02-01

13
papers

142
citations

1477746

6
h-index

1281420

11
g-index

13
all docs

13
docs citations

13
times ranked

217
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of scales to measure dystonia and choreoathetosis in children with dyskinetic cerebral palsy. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 786-795.	1.1	55
2	Myoclonus–dystonia caused by <i>GNB1</i> mutation responsive to deep brain stimulation. <i>Movement Disorders</i> , 2019, 34, 1079-1080.	2.2	22
3	Intrathecal baclofen therapy in children: an analysis of individualized goals. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 367-373.	1.1	17
4	Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit. <i>BMJ Open</i> , 2017, 7, e015863.	0.8	14
5	Identification, classification and assessment of dyskinesia in children with cerebral palsy: A survey of clinicians. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 432-438.	0.4	8
6	The Dyskinetic Cerebral Palsy Functional Impact Scale: development and validation of a new tool. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 1469-1475.	1.1	8
7	Implementing accurate identification and measurement of dyskinesia in cerebral palsy into clinical practice: A knowledge translation study. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 1351-1356.	0.4	5
8	The Impact of Intrathecal Baclofen Therapy on Health-related Quality of Life for Children with Marked Hypertonia. <i>Developmental Neurorehabilitation</i> , 2020, 23, 542-547.	0.5	5
9	Current Australian clinical practice in use of botulinum toxin to manage paediatric hypertonicity. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1662-1665.	0.4	3
10	Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy. <i>Brain and Development</i> , 2022, 44, 153-160.	0.6	3
11	A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy. <i>BMC Pediatrics</i> , 2021, 21, 368.	0.7	2
12	078–Deep brain stimulation (DBS) for dyskinetic cerebral palsy: a pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A32.1-A32.	0.9	0
13	Better Together: the Australasian Academy of Cerebral Palsy and Developmental Medicine champions equity. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 356-356.	1.1	0